As a prelude to assessing the relationship of chromosome alterations to clinical outcome in ovarian carcinoma, we report on the cytogenetic analysis on short-term cultures from 54 patients. All patients had histopathalogically confirmed malignancy, with the majority of cases demonstrating serous ovarian adenocarcinomas. Structural alterations were evident in 52 cases, whereas numeric changes were identified in 13 cases. The most notable numeric abnormalities were loss of the X-chromosome (9/13 total cases) and +7 (3/9 diploid cases). Structural alterations most frequently involved chromosomes 1, 3, 6, 7, 11, and 12. Chromosomal breakpoints were shown to cluster in several chromosomal banding regions, including lp36, lp11-q21, 3p23-plO, 7p (especially 7p22), llp, 11q, 12p13-q12, and 12q24. The frequency of structural alterations involving the following chromosome arms was found to be significantly increased: lp (p <~ 0.01), 7p (p < 0.01), 11p (p < 0.01), 11q (p < 0.05), and 12p (p < 0.05). An analysis of the net gain or loss of chromosome segments was also performed, with the most consistent tendency observed being over-representation of lq and chromosome 7, deletion of lp, and loss of the X chromosome.
INTRODUCTION
Ovarian cancer continues as the leading cause of death from gynecologic cancer in the United States, with an estimated 20,700 new cases and 12,500 deaths in 1991 [1] . This cancer is most common in Western countries, with the incidence per 100,000 population being highest in Sweden (21.0) but nearly as high in white females in the United States (15.6) [2] . In contrast, the incidence is as low as 3.1 per 100,000 in Japan [2] .
Previously described prognostic factors from prospective, randomized studies of patients with stages III and IV disease include: patient age <50 years; performance status 0-1 {SWOG); stage III disease; absence of macroscopic tumor at the end of initial exploratory laparotomy; and well-differentiated (i.e., grade 1] serous cystadenocarcinoma histopathology [3] [4] [5] [6] [7] [8] . Commonly, the most important predictor of survival in patients with stage III c~ncers is the degree of residual disease remaining following initial exploratory laparotomy [3] [4] [5] . Additionally, the serum CA-125 concent_ration after chemotherapy may prove an independent prognostic factor with respect to survival duration in patients with advanced ovarian cancer [9] [10] [11] [12] [13] . However, there is also an ongoing search for a pretreatment predictor of prognosis. A potentially important area is the identification of specific cytogenetic abnormalities in the ovarian tumors.
Relatively little is known of specific cytogenetic alterations in ovarian cancer, particularly for tumor karyotypas from the primary specimens and regional metastatic sites at initial laparotomy. Metastatic specimens {including ascites fluids) show frequent rearrangements {or allelic loss of heterozygosity) involving 3p, 6q, 1113, 17q, and 17p13 [14] [15] [16] . However, the only karyetypic alteration that has been shown to be associated with ovarian cancer as a primary change is + 12, also found in benign tumors (fibromas, thecomas, and adenomas of the ovary) [15] . Clearly, given the importance of this tumor, further knowledge regarding the cytogenetics of this disorder would be useful. In this report, we describe cytogenetic findings in 54 cases of previously unpublished ovarian carcinoma.
MATERIALS AND METHODS

Patient Population
Solid tumor samples for cytogenetic analysis were obtained from patient with clinical ovarian cancer at initial laparotamy. During the period from January 1987 to April 1991, 480 ovarian tumor samples were received; 317 of these samples
33
Cancer Genet Cytogenet 73: 33-45 (1994) 01654608/94/$07.00 (66%) were successfully cultured. From this group 169 sampies {from 165 patients) met eligibility criteria for study inclusion, specifically: origin from a solid tumor sample from a newly diagnosed patient previously untreated for epithelial ovarian cancer. Of these 165 patients, clonal abnormalities were detected in 84 patients (~ 50%). The present series describes the first 54 patients with clonal abnormalities on whom systematic histopathologic review has been completed.
Histopathologic review of tumor tissue confirmed the diagnosis of primary ovarian epithelial malignancy. Histelogic classification based on standard WHO criteria [17] was performed independent of karyotype date. Tumors were graded histologically as well, moderately, or poorly differentiated according to a grading system utilizing a combination of architectural, cytoplasmic, and nuclear features as described by Russell and BAnnatyne [18] . Clinical staging was based on FIGO classification criteria [19] .
Cytosene~c Analysis
Cytogenetic nnalysis was performed as previously described [20] after short-term culture (1-32 days, mean = 8.2 days) in either McCoy's, RPMI-1640, or modifications of L15 medium [21] . Typically, 25 or more metaphases were counted and examined, and a minimum of five ~s [and generally 10 or more) of the modal population ware prepared. Description of karyotypic abnormalities followed the recommendations of the ISCN [22, 23] . Structural abnormalities were identified as clonal if found in two or more cells. Numeric changes (two or more cells for gain, three or more cells for loss) were described relative to ploidy of the abnormal modal population, as per the recommendations of the Cancer Cytogenetics Supplement [1991] , and these were determined only if a mode or modal range represented at least 20% of the cells counted.
Statilfdcal Analysis of ~eomosomal Alterations
The frequency of occurrence of structural abnormalities was analyzed using the statistical approach of Brodeur et al. [24] . This method allows assessment of statistically significant involvemant of particular chromosome arms. With this method, the expected probability of structural abnormalities is assumed to be proportional to chromosome arm length and chromosomal abnormalities are assumed to occur as independent events.
Segment Representation Profiles
An analysis to assess the recurrent gains or losses of specific chromosomal segments was performed. We have termed this approach a chromosomal segment representation profile (CSRP) [25] . This analysis takes into account both gain and loss of normal chromosomes and the presence of structurally altered homologs, with the combined results producing a visual representation of the net gain or loss of chromosomes or chromosomal segments. CSRP analysis was performed only in cases in which the abnormal cell populations had defined modes {~20% of cells examined} and karyotypes. Additionally, CSRPs ware all described relative to diploid, as we wished to study the effects of karyotype alterations acquired by the normal progenitors. T87-112  58  Serous  III  Poor  T87-134  64  Serous  IV  Poor  T88-173  57  Serous  IV  Moderate  T88-178  62  Undifferentiated  I  Poor  T88-183  71  Serous  III  Poor  T88-207  50  Serous  III  Poor  T88-267  65  Endometroid  III  Poor  T88- A majority of cases had modes that were near diploid, with one case being pseudo-diploid (1"88-411). In six cases, the mode was normal diploid, but the abnormal cell component {sideline) did not have a modal number as defined by 920% of cells examined. Seven cases were bimodal in chromosome numbers, with one mode of 46 in each case.
Eleven cases were so heterogeneous or complex that no modal numbers could be determined.
Normal metaphases were found in 12 cases, presumably representing mixtures of tumor and nontumor cells. In 22 cases extremely complex abnormal chromosome preparations were obtained. These cells typically contained fragmented chromosomes, quadriradials and/or triradials, and varying complex structural rearrangements such that complete karyotype descriptions were not possible. This finding is characteristic of ovarian carcinomas but rare in other tumors [26] . An example of such a cell is shown in Figure  1 . The small proportion of cases with clonal numeric abnormalities is no doubt due in part to the presence of these corn- 
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e Unspecified regional metastatic sample from the lower abdominal cavity.
plexly abnormal cells that could not be fully characterized. Although cases with AX and NX profiles contained highly abnormal and only partially analyzable metaphases {as shown in Figure 1A) , it was possible to identify clonal structural abnormalities in these cases. The clonal rearrangements identified from a case with an AX profile, T90-248, are presented in Figure lB . Cases were assigned to karyotype profiles {defined in footnote, Table 2} to indicate whether or not they contained mixtures of normal, abnormal, or complexly abnormal cells {Ta-ble 2). The overall distribution of karyotype profiles was: 17 cases AX {32%}, 24 cases AA {44%), eight cases AN {15%}, and five cases NX {9%). An overview of the relationships between karyotype profile and ploidy of mainlines is shown in Hgure 2. Not surprisingly, among cases with near-diploid modes there was a higher proportion of cases with NX and AN karyotype profiles, whereas cases that had no defined mode had exclusively AX or AA profiles.
Examples of representative G-banded karyograms from three cases are shown in Figures 3-5 . These karyotypes demonstrate abnormalities found in pseudodiploid, hyperdiploid, and polyploid cells.
There was a tendency to loss of chromosomes relative to ploidy level, particularly for the near-triploid cases. The most common numeric abnormality was loss of at least one X chromosome, observed in 9/13 cases (six near-diploid, and three near-triploid abnormal modes). The only chromosomes present in excess copy number (one or more additional homologs) in near-diploid cases were chromosomes 7 (3/9 cases), 8, and 12 (one case each). The significance of numeric abnormalities relative to triploid is not clear. Two cases showed only numeric alterations. The stemline and mainline karyotype of T89-232 was 4ZXX, + 8 (in 60% of the metaphases examined), whereas the sideline in this case was 48,XX, + Z + 8 (40%). In case T90-064, the mainline was 46,XX and appeared normal, whereas the sideline was 45,X (43% of cells). Because of the possibility that clonal loss of X represented a constitutional chromosomal abnormality, peripheral blood was obtained and analyzed, confirming the suspicion that this patient was a previously undiagnosed Turner's syndrome mosaic. This patient's case will be reported in more detail separately.
A detailed description of clonal structural abnormalities and their profiles {i.e., karyotype mixtures) is given in Table  2 . Among the 52 patients with structural abnormalities, chromosomes 1, 6, Z 11, and 12 showed the highest frequency of involvement. Abnormalities of chromosome 1 were detected in 32/52 patients [62%}, whereas 19/52 (37%) had abnormalities of chromosome 6, 21/52 {40%) had abnormalities of chromosome 7, 27/52 (52%) had abnormalities of chromosome 11, and 18/52 [35%) had abnormalities of chromosome 12. The distribution of chromosomal abnormalities according to arm involved in shown in Figure 6 . Using the method of Brodeur et al. [24] , the frequency of involvement of the following chromosome arms was found to be significantly increased: lp [p < 0.01), 7p {p < 0.01), llp {p < 0.01), llq (p < 0.05), and 12p {p < 0.05). A number of structural abnormalities involved chromosome 3, but the frequency of these anomalies was not statistically significant. A summary of all breakpoints identified collectively f~m clonal abnormalities in this set of patient samples is shown in Figure 7 . The chromosomal regions most often affected by structural abnormalities were lp36, 1p11-q21, 3p23-p10, 7p {especially 7p22), all of chromosome 11, 12p13-q12, and 12q24. Few recurring structural abnormalities were identified, except for translocations of frequently unknown material to lp36. Examples of these translocations are shown in Figure  8 . In Figure 8 , the translocated material in the lp + marker from case T89-148 was thought to be derived from a chromosome 11, while the origin of translocated material in lp + markers from all other cases remains unidentified.
Isochromosomes were found in seven cases and included i(lq) in two cases, and i{6p) in two cases. Cytologic evidence of possible gene amplification in the form of homogeneously staining regions {HSRs} was found in 12 cases {two cases each on 6p, llp, and 12p, and one case each on Ip, 2q, 4q, 7p, 17q, and 18q). Apparently simple, terminal deletions of chromosomes were found in 46/54 cases {85%}, including deletions of Ip [seven cases}, lq {six cases}, 6q {five cases}, and 7q and llp {four cases each}. Generally more common were unbalanced and nonreciprocal translocations sometimes involving material of uncertain origin.
In this series of patients, it was possible to perform CSRP analysis on 13 patients. These results, summarized in Figure Z document a tendency to gain chromosomes or chromosomal segments, relative to diploid. Net gain most notably involved the long arm 'of chromosome I and all of chromosome 7 {often with material of unknown origin translocated to the 7pter), while net loss involved the X chromosome and deletion of lp.
An interesting relationship between chromosome 6 abnormalities and histology was noted in our patient series. Specifically, 83% {5/6 cases) of tumors with an undifferentiated histology displayed structural rearrangements of chromosome 6, whereas only 32 % {12/38 cases} of serous tumors and 25% {2/8 cases) of endometrioid tumors had abnormalities of chromosome 6 (p = 0.04, ;(z test}. In contrast, structural alterations of chromosome I {which were the most frequent} did not seem to be related to histology in our series, where 67% of undifferentiated {4/6 cases}, 63% of serous {24/38 cases), and 50% of endometrioid {4/8 cases) tumors displayed such rearrangements.
DISCUSSION
Prior to initiating therapy for solid or hematologic malignancies, it is useful to estimate the patient's relative prognosis to fully inform them of the risk/benefit ratio as well as to select the most appropriate and potentially effective treatment. There are well-documented prognostic factors associated with advanced ovarian cancer, including patient age, performance status, stage, degree of residual intmpelvic and intra-abdominal tumor after resection, and histologic grade of tumor. Although each characteristic has been associated with survival in retrospective AnAlyses [3] [4] [5] [6] [7] [8] , there is a continued search for tumor-specific factors that prospectively and independently predict ovarian cancer patient survival. We evaluated clonal karyotype abnormalities in 54 patients newly diagnosed with advanced ovarian cancers in an attempt to identify specific cytogenetic changes which may be associated with the prognosis of this disease.
Our cytogenetic findings both confirm and extend our earlier observations [26] and are in general agreement with those of other investigators. For example, Belle et al. [27] reported finding karyotypic heterogeneity in ovarian fluids where no two cells displayed the same karyotype, but they could be shown to be clonally derived. Many samples in our study were similarly so heterogeneous that modal numbers could not be definitively determined, although structural abnormalities could be identified.
It has been previously shown that abnormalities of chromosomes I and 6 are common in ovarian cancer. Other studies on predominantly malignant effusions have shown that chromosome 3 is also frequently invotved in rearrange- ments in these tumors [27, 28] . In a recent study of primary ovarian tumors, the chromosomes most frequently altered were 1 > 11 > 3 > 7 [29] , whereas a similar study by Pejovic et al. [30] found that the chromosomes most frequently involved in structural rearrangements were 1, 6, and 11. These authors also reported the findings of translocations of unknown material to 19p in 7/11 cases with bilateral ovarian carcinoma, and suggested that this might represent a specific marker characterizing a subset of patients. Although in our patient series we did not find 19p + markers, we did identify structural abnormalities involving 19q13. Similarly, Belle et al. [31] found 2/20 cases with 19q +, rather than 19p +, markers, and Whang-Peng et al. [28] found 12/29 cases with clonal structural abnormalities to have 19q + markers of unknown origin. Differences in detection of 19p + vs. 19q + markers and the incidence of structural abnormalities regarding chromosome 19 may represent a function of differing interpretations or geographic heterogeneity of neoplasiaassociated chromosome aberrations [32] . In a study of stages HI and IV ovarian carcinoma, Volta et al. [33] found that patients with aneuploid tumors had a reduced survival compared to patients who did not have aneuploid tumors. One phenomenon which might relate to tumor progression and acquisition of increasing chromosome number is amplification of cellular oncogenes. Sasano et al. [34] looked for amplification of the c-myc, int-2, and c-arbB-2 oncogenes in benign and malignant ovarian tumors and showed that nearly half of the carcinomas that displayed amplification were aneuploid carcinomas, while none of the benign tumors showed gene amplification. In addition, they demonstrated a relationship between gene amplification and the serous histologic sub-type. In our patient sample of predominantly stage HI and IV ovarian carcinomas, 12/54 [22 %} cases showed cytologic evidence of gene amplification in the 
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form of homogeneously staining regions {I-ISRs}. "lbn of these {83%] were serous tumors, one was endometrioid, and one was an undifferentiated stage I tumor. While most tumors in this series displayed numerous and complex karyotypic alterations, some cases showed few abnormalities, and two of these had only numeric changes. Clonal gain of chromosomes 7 and 8 were the only abnormalities in "1"89-232, and loss of X was found in the tumor from patient T90-064, who was shown to be a previously undiagnosed Turner's syndrome mosaic. Although the -X was a constitutional abnormality in this patient, it is interesting that CSRP analysis showed that loss of the X chromosome was one of the most consistent findings in our series. Other cases were near-diploid and showed simple karyotypes with both numeric and structural abnormalities. In case T89-321, a well-differentiated stage I endometr/oid carcinoma, the mainline karyotype was 49,XX, +del{3)[q21), +7, +7. The stemline karyotype of T89-154, a wall-differentiated stage HI serous carcinoma, was 45,X, -X, i(1}{ql0}, + 7, -22, while the mainline was 46,idem with random numeric gains. In a case of a poorly differentiated stage HI carcinoma with an undifferentiated histologic sub-type, T88-286, the modal karyotype was hypodiploid [45] and displayed balanced, reciprocal translocations, unbalanced translocations, i{lq], and clonal loss of 15, 16, 19 , and both X chromosomes. A representative karyotype from this case is given in Figure 4 .
These cases are of interest because they contained a single or few chromosome abnormalities, which may represent ~rimar~' changes important in those tumors' initi~on, promotion, and/or early development. Nine of 13 cases in which clonal numeric abnormalities were identified {six neardiploid and three near-triploid} showed loss of at least one X chromosome relative to ploidy level. Loss of X chromosomes has also been previously reported by others. For instance, Pejovic et al. [30] found loss of the X in 3/4 abnormal near-diploid cases of bilateral ovarian carcinoma and, relative to ploidy level, in 7/7 near-triploid and near-tetmploid tumors. Tanaka et al. [35] found loss of X in 8/9 ovarian cancer cases, and Pejovic et al. [36] found loss of X in 8/9 karyotypically abnormal carcinomas, relative to ploidy level. Furthermore, Pejovic et el. [37] found that loss ofX wes the only anomaly in the karyotype of an ovarian adenofibroma (although they also found + 12 alone or in combination with additional numeric changes in six other benign ovarian tumors). It is tempting to speculate that loss of X may be a primary and/or predisposing event in ovarian cancer initiation.
While clonal losses were more common than gains (relative to ploidy levels in both diploid and triptoid tumors), the most common gain of at least one normal homolog involved chromosome 7 {3/13 cases, all diploid}. In the study by Pejovic et el. [38] , cytnganetic studies of four welldifferentiated malignant epithelial tumors {including a seropapfllary ovarian adenocarcinonm and a squamous cell carcinoma which developed on an ovarian dermoid cyst) showed only simple numeric karyotype aberrations. Gain of chromosome 7 was common to all four cases. Gain of chromosome 7 followed by structural abnormalities of that chro- 18 mosome may be an early, if not primary, change in at least a subset of patients. Trisomy 7 as a sole karyotype abnormality has been reported in a number of epithelial, mesenchymal, and neurogenic neoplasms, as well as in nonneoplastic tissues [39] . Although + 7 alone may not strictly be a marker of malignant cells, it is not known whether + 7 is a neutral karyotype imbalance or if it confers growth advantages on affected cells. Nonetheless, the significant number of chromosome 7 break points identified in our patient series and over-representation rivaled only by chromosome 1 suggests that chromosome 7 imbalances are associated with, if not a contributing or predisposing factor to, early tumor progression.
The only other normal homologs gained in near-diploid tumors in this series were chromosomes 8 and 12 {one case each). We have previously reported on an ascites fluid from ovarian cancer in which the only karyotypic abnormalities were inv(3), + 8, + 12, + 20 [40] . Additionally, we have observed other cases of ovarian carcinoma with very simple karyotypes which have numeric abnormalities, including + 8 and + 12, as sole abnormalities {unpublished data}. It is possible that gain of chromosome 12 followed by structural rearrangement accompanying tumor progression is an important characteristic of a subset of patients with ovarian carcinoma. Evidence for this includes the finding by Pejovic et al. [3Z 41] of + 12 in some benign ovarian tumors and ovarian carcinomas, and the finding of frequent structural abnormalities of chromosome 12 in the present series.
Structural alterations involving chromosome I were found in 62 % of the samples in this case series, an observation reported frequently in all human solid tumors. However, two of our cases with very simple karyotypes, T89-154 and I"88-286, displayed alterations of chromosome I [i{lq}], suggesting that rearrangements involving chromosome I may be an early event in tumor progression. In our patient series, we also noted a subset of patients with translocations of unknown material to chromosome band Ip36. These markers are similar in appearance to alp + marker in a published karyotype of alterations of chromosome 6 in our patient series correlated with an undifferentiated histologic sub-type, rather than the much more common serous sub-type, and were quite frequently found in cases with the most complex ~ypes.
In summary, our findings are consistent with the idea that nonrandom chromosome abnormalities can be identified in ovarian carcinoma and frequently involve chromosomes 1, 3, 6, 7, 11, and 12. Some of these keryotypic abnormalities (involving chromosomes 1, 3, and 7, or loss of the X} may be important to tumor initiation, whereas others {possibly involving 6, 11, and 12) may be related to tumor progression, histology, or metastasis. While further cytogenetic studies are warranted, examination of possible clinicopathologic correlations are underway and may shed light on the biologic significance of these chromosome rearrangements.
We would like to acknowledge members of the Gynecologic Cancer Committee of the Southwest Oncology Group for forwarding fresh humAr~ ovarian cancers to the Arizona Cancer Center for cytogenctic analysis. The major tumor contributors include Drs. Earl Surwit, A1 Bonebrake, Darryl Wallace, Ken Hatch, and Francisco Ampuero. We would also like to thank Lee Wisner for technical assistance in the preparation of the figures. This work is supported by NCI grant CA-41183. Pejovic et al. [42] , and another by Roberts and Tatersall [43] . Additionally, lp + markers were reported in 2/9 cases by Tanaka et al. [35] and 10/29 cases by Whang-Peng et al. [28] . In most cases, translocated chromosomal segments are too small to identify their origins by standard banding methods. Future studies are planned combining chromosome microdissection [44] and fluorescent in situ hybridization methods in the hopes of revealing whether these represent consistent, specific translocations or only a common breakpoint involving translocations with varying donor chromosomes.
Karyotype abnormalities of chromosome 3 may also be important to early tumor progression in some patients because + del{3) {resulting in gain of the 3p and praximal 3o.) was the only structural abnormality in our case "I"89-321 (a patient with stage I disease). Bel]o et al. [31] reported a case of a pleura] fluid from a patient with an ovarian primary whose karyotype only displayed + 3, and we have previously reported on the study of serial ascites fluid specimen samples where the stemll-e karyotype was 50,XX,inv{3}, + inv(3), + 8, +12, + 20 [40] . A number of our cases with more complex s also had rem'rangements of chromosome 3, a finding that is in agreement with other studies.
Our findings suggest that certain karyotypic alterations in ovarian cancer may be related to histology. Specifically,
